Scarica l'app Stockscreener
29.88
1.01%
0.30
Dopo l'orario di chiusura:
29.84
-0.04
-0.13%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ARQT Giù?
Forum
Previsione
Precedente Chiudi:
$29.58
Aprire:
$29.175
Volume 24 ore:
1.70M
Relative Volume:
0.77
Capitalizzazione di mercato:
$3.66B
Reddito:
$59.61M
Utile/perdita netta:
$-262.14M
Rapporto P/E:
-7.6224
EPS:
-3.92
Flusso di cassa netto:
$-247.49M
1 W Prestazione:
+2.89%
1M Prestazione:
-3.71%
6M Prestazione:
+117.15%
1 anno Prestazione:
+95.68%
Intervallo 1D:
$28.86
$30.26
Intervallo di 1 settimana:
$28.49
$30.60
Portata 52W:
$11.13
$31.77
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
Nome
Arcutis Biotherapeutics Inc
Settore
Industria
Telefono
805-418-5006
Indirizzo
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Confronta ARQT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
29.88 | 3.62B | 59.61M | -262.14M | -247.49M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-25 | Iniziato | Goldman | Neutral |
| 2024-12-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-08-28 | Iniziato | Jefferies | Buy |
| 2024-01-03 | Aggiornamento | Mizuho | Neutral → Buy |
| 2023-10-26 | Downgrade | Mizuho | Buy → Neutral |
| 2023-10-13 | Downgrade | Goldman | Buy → Neutral |
| 2022-09-07 | Iniziato | Needham | Buy |
| 2022-03-17 | Iniziato | Goldman | Buy |
| 2021-06-30 | Iniziato | Mizuho | Buy |
| 2021-05-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-09 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-10-08 | Iniziato | Truist | Buy |
| 2020-02-25 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-02-25 | Iniziato | Cowen | Outperform |
| 2020-02-25 | Iniziato | Goldman | Neutral |
| 2020-02-25 | Iniziato | Guggenheim | Buy |
Mostra tutto
Arcutis Biotherapeutics Inc Borsa (ARQT) Ultime notizie
Earnings Report: Will Arcutis Biotherapeutics Inc. stock beat EPS estimatesJuly 2025 Rallies & Reliable Entry Point Trade Alerts - ulpravda.ru
Is Arcutis Biotherapeutics Inc. stock a buy before product launches2025 Key Highlights & Reliable Intraday Trade Plans - ulpravda.ru
How Arcutis Biotherapeutics Inc. stock compares to growth peersJuly 2025 News Drivers & Scalable Portfolio Growth Methods - ulpravda.ru
Arcutis Bio EVP Burnett sells $72k in shares By Investing.com - Investing.com Canada
Arcutis Bio EVP Burnett sells $72k in shares - Investing.com India
Arcutis Biotherapeutics, Inc.Common stock (NQ: ARQT - FinancialContent
Arcutis Biotherapeutics, Inc. (ARQT) Stock Analysis: Revenue Surge and Analyst Consensus Signal Opportunity - DirectorsTalk Interviews
Arcutis BiotherapeuticsFocusing On ZORYVE Market Expansion And Pipeline Growth - RTTNews
(ARQT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Arcutis Biotherapeutics (NASDAQ:ARQT) Raised to "Strong-Buy" at Wall Street Zen - MarketBeat
Arcutis Biotherapeutics CEO Todd Watanabe sells $245,122 in shares - MSN
Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Sells $49,552.40 in Stock - MarketBeat
Arcutis Biotherapeutics EVP Burnett sells $49,560 in shares By Investing.com - Investing.com South Africa
Arcutis Biotherapeutics EVP Burnett sells $49,560 in shares - Investing.com
Arcutis Biotherapeutics stock today: ARQT ends 2025 up 3.4% as traders eye FDA, earnings dates - TechStock²
Arcutis stock (ARQT) in focus after insider sale notice as U.S. markets shut for New Year’s Day - ts2.tech
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Up 3.4%Still a Buy? - MarketBeat
Arcutis Biotherapeutics stock pops today as ARQT bucks biotech dip into year-end trade - ts2.tech
Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Rating Lowered by Zacks Research - MarketBeat
Arcutis Biotherapeutics Earnings Notes - Trefis
Arcutis Biotherapeutics stock slides today as biotech pulls back, ARQT down nearly 3% - ts2.tech
Arcutis Biotherapeutics, Inc. (ARQT) Stock Analysis: A 10.73% Potential Upside Amidst Robust Revenue Growth - DirectorsTalk Interviews
Arcutis Biotherapeutics, Inc. $ARQT Shares Sold by Simplify Asset Management Inc. - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Downgraded by Wall Street Zen to Buy - MarketBeat
Is Suvretta’s Stake Cut and FDA’s Pediatric Review Acceptance Altering The Investment Case For Arcutis Biotherapeutics (ARQT)? - Yahoo Finance
Arcutis Stock Is Up 100% in a Year but Here’s Why One Fund Still Sold 1 Million Shares - Yahoo Finance
Arcutis Stock Is Up 100% in a Year but Here’s Why One Fund Still Sold 1 Million Shares - The Motley Fool
How Low Can Arcutis Biotherapeutics Stock Really Go? - Trefis
Why Arcutis Biotherapeutics Inc. stock remains resilientRate Cut & Weekly Watchlist of Top Performers - Улправда
Perpetual Ltd Increases Stake in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Will Arcutis Biotherapeutics Inc. stock gain from strong economyJuly 2025 Pullbacks & Technical Pattern Alert System - Улправда
Are Medical Stocks Lagging Compass Therapeutics, Inc. (CMPX) This Year? - Yahoo Finance Australia
Is Arcutis Biotherapeutics Inc. stock attractive for growth ETFsJuly 2025 EndofMonth & Momentum Based Trading Ideas - DonanımHaber
Price Action: Why Arcutis Biotherapeutics Inc. stock remains resilientJuly 2025 Review & Low Risk Entry Point Tips - Улправда
Investor Mood: What Wall Street predicts for Arcutis Biotherapeutics Inc. stock priceJuly 2025 Selloffs & Weekly Setup with ROI Potential - Улправда
What Wall Street predicts for Arcutis Biotherapeutics Inc. stock priceJuly 2025 Spike Watch & Detailed Earnings Play Alerts - Улправда
Zacks Industry Outlook Arcutis, Amicus and ANI - The Globe and Mail
Squarepoint Ops LLC Has $2.35 Million Holdings in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Insider Selling: Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Sells 11,500 Shares of Stock - MarketBeat
Looking Into Arcutis Biotherapeutics Inc's Recent Short Interest - Sahm
Arcutis Biotherapeutics Executive Sells Shares - TradingView — Track All Markets
Arcutis Biotherapeutics Insider Sold Shares Worth $332,851, According to a Recent SEC Filing - marketscreener.com
VP Burnett Sells 11,500 ($332.9K) Of Arcutis Biotherapeutics Inc [ARQT] - TradingView — Track All Markets
Arcutis (ARQT) CMO exercises options, sells 11,500 shares in plan trade - Stock Titan
This Biotech Stock Could Cure Your Portfolio's Pain - Finviz
Assessing Arcutis Biotherapeutics After 99% YTD Surge and Mixed Valuation Signals - Yahoo Finance
This biotech stock could cure your portfolio's pain - MSN
Arcutis Biotherapeutics, Inc. $ARQT Holdings Boosted by Frazier Life Sciences Management L.P. - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Raised to Strong-Buy at Wall Street Zen - MarketBeat
Gilder Gagnon Howe & Co. LLC Purchases 59,712 Shares of Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Arcutis Biotherapeutics Inc Azioni (ARQT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):